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Summary Optimal management of prosthetic heart valve obstruction (PHVO) remains contro-
versial even though surgery is usually recommended. To better deﬁne the efﬁcacy and safety of




We analysed initial results and follow-up data from a large, retrospective, single-centre series,
comparing ﬁbrinolysis and surgery in patients with PHVO treated over 20 years. Two hundred
and sixty-three consecutive episodes of PHVO in 210 patients, mainly left sided, were managed
in our institution by either ﬁbrinolysis (n = 127) or surgery (n = 136). Early clinical evolution was
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rinolyse peut se justiﬁer dans des cas sélectionnés. Les résultats à long terme montrent des
résultats signiﬁcativement meilleurs dans le groupe chirurgical en termes de récurrence et de
mortalité.
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assessed in terms of haemodynamic success and complications. Concerning early results, there
were no signiﬁcant differences between the two groups in terms of mortality (10%). However,
haemodynamic success was signiﬁcantly more frequent in the surgical group (89% versus 70.9%
p < 0.001), embolic episodes were signiﬁcantly more frequent in the ﬁbrinolysis group (15% ver-
sus 0.7%, p < 0.001), as were total complications (25.2% versus 11.1%, p = 0.005). Long-term
follow-up, with a mean duration of 6 years (range: 0—20), was obtained and showed signif-
icantly better results in the surgical group in terms of recurrence (p = 0.021) and mortality
(p = 0.002). In univariate and multivariable analyses, NYHA functional class at presentation was
a strong predictor of late death (p < 0.01). Management of patients during the pre- and post-
TEE eras was signiﬁcantly different, since introduction of TEE surgery has become the preferred
therapeutic strategy. Results of this extensive single-centre experience indicate that since the
introduction of TEE, surgery is more frequently performed than ﬁbrinolysis due to the improve-
ment of thromboembolic risk assessment. Furthermore, prompt surgical treatment is associated
with a better early success rate and a signiﬁcantly lower incidence of complications than ﬁbri-
nolysis in left-sided PHVO. However, ﬁbrinolysis may be justiﬁed in selected cases. Long-term
follow-up showed signiﬁcantly better results in the surgical group in terms of recurrence and
mortality.







Résumé La prise en charge optimale des obstructions de prothèses valvulaires mécaniques
demeure controversée, même si la chirurgie est habituellement recommandée. L’objectif de
cette étude est de mieux déﬁnir l’efﬁcacité et la sécurité de la ﬁbrinolyse versus la chirurgie
en comparant les périodes pré- et postintroduction de l’échographie transœsophagienne (ETO).
Il s’agit d’une large série rétrospective (20 ans) monocentrique, comparant la ﬁbrinolyse et la
chirurgie chez des patients présentant une thrombose de prothèse valvulaire mécanique. Deux
cent soixante-trois épisodes consécutifs de thrombose de prothèse valvulaire ont été pris en
charge chez 210 patients, essentiellement des atteintes du cœur gauche qui furent traitées dans
notre institution, soit par ﬁbrinolyse (n = 127), soit par chirurgie (n = 136). Les résultats préco-
ces ont été étudiés en termes de succès hémodynamique ou de complications. Il n’apparaît pas
de différence signiﬁcative entre les deux groupes en terme de mortalité précoce. Cependant,
le succès hémodynamique est signiﬁcativement plus fréquent dans le groupe chirurgie (89 %
versus 70,9 % ; p < 0,005), les épisodes emboliques sont signiﬁcativement plus fréquents dans le
groupe ﬁbrinolyse (15 % versus 0,7% ; p < 0,01), de même que les complications totales (25,2 %
versus 11,1 % ; p < 0,01). En ce qui concerne le suivi à long terme sur une durée moyenne de
six ans (0—20 ans), nous démontrons des résultats signiﬁcativement meilleurs dans le groupe
chirurgical en terme de récurrence (p = 0,021) et de mortalité (p = 0,002). En analyse uni- et
multivariée, la classe fonctionnelle de la NYHA lors de l’épisode initial est un prédicteur fort de
décès tardif. La prise en charge de ces patients avant et après l’introduction de l’ETO apparaît
signiﬁcativement différente, puisque depuis l’introduction de l’ETO, la stratégie chirurgicale
devient la stratégie de choix. Les résultats de cette étude monocentrique extensive indique
que depuis l’introduction de l’ETO la chirurgie est plus fréquemment utilisée que la ﬁbri-
nolyse dans la prise en charge des obstructions de prothèse valvulaire mécanique du fait de
l’amélioration de l’évaluation du risque thromboembolique que peut engendrer la thrombol-
yse. De plus, la prise en charge chirurgicale rapide est associée à un meilleur résultat initial,
à une diminution signiﬁcative des complications par rapport à la ﬁbrinolyse. Cependant, la ﬁb-HVO is a serious complication of mechanical prosthetic
alves, mainly due to thrombosis, which is associated with
high mortality rate and thus needs immediate diagnosis












































mManagement of prosthetic heart valve obstruction: Fibrinoly
even though surgery (thrombectomy or valve replacement)
is normally recommended in such cases [1—8]. High sur-
gical mortality rates have been reported, in particular in
patients with a poor clinical status [9—12]. Fibrinolysis was
proposed as an attractive alternative as early as 1971,
but its use remains controversial because of the risk of
embolism [13—17]. Recent studies have suggested that cur-
rent guidelines overemphasize the potential side effects of
ﬁbrinolysis, since most of the data were based on older
prostheses and may not be applicable to new generation
bileaﬂet valves. Furthermore, recent studies have used TEE
to characterize PHVO and to avoid lysis in large peduncu-
lated thrombi [18—22]. Therefore, some recent reports and
reviews recommend ﬁbrinolysis as the ﬁrst-line approach
in the management of prosthetic valve thrombosis in the
post-TEE era [23—25].
We analysed initial results and follow-up data from a
large, retrospective, single-centre series, comparing two
non-randomized cohorts of patients with PHVO treated with
ﬁbrinolysis or surgery, in order to better deﬁne the initial
efﬁcacy and safety of these two treatment modalities, in
the pre- and post-TEE eras.
Methods
All consecutive patients diagnosed with PHVO at our insti-
tution over a 20-year period were included in the study.
Patients were identiﬁed from the databases of medical
and surgical departments in our institution, which is a
referral centre for southwestern France. Approximately
17,250mechanical heart valves were implanted between
1978 and 2001.
The choice of therapeutic strategy was made by treating
physicians based on clinical judgment. In all cases, treat-
ment was selected in agreement with the surgical team.
The criteria used to select patients for either ﬁbrinolysis or
surgery changed over time. At the beginning of this study,
more than 25 years ago, ﬁbrinolysis appeared an attractive
alternative to surgery because of the high surgical mortal-
ity associated with PHVO. However, with the introduction
of TEE, the mechanism of obstruction was better deﬁned
(pannus, thrombus) [23,24] and accordingly, indications for
ﬁbrinolysis were better deﬁned [25—27] (excluding huge
thrombi and pannus), even though its use remains contro-
versial.
Diagnosis of PHVO was based on clinical examination and
diagnostic procedures. The main clinical signs of obstruction
were dyspnoea, congestive heart failure or embolism. As
far as auscultation was concerned, diminished or abolished
clicks with new systolic or diastolic murmurs were noted in
the majority of patients with an obstruction.
Early diagnostic procedures relied mainly on catheteri-
zation, which was replaced rapidly by cineﬂuoroscopy, TTE
and more recently by TEE [28—34].
As previously reported, in most cases, thrombosis
occurred due to the lack of adequate anticoagulant. In our
series, 76% of patients were receiving subtherapeutic (inter-
national normalized ratio [INR] < 2) doses of anticoagulants
at the time of the diagnosis. In 23% of patients, this was due
to discontinuation of anticoagulation (bridging) for extrac-






With the evolution of ﬁbrinolytic agents, different pro-
ocols have been used. At the beginning of our experience,
ong-course protocols with streptokinase or urokinase were
ypically used. In the past 16 years, tissue plasminogen acti-
ator (rtPa) or accelerated short-course streptokinase was
sually prescribed. The ﬁbrinolytic protocols have been
escribed in detail elsewhere [14]. Evaluation of ﬁbrinolysis
fﬁcacy was based on clinical data, TTE and cineﬂuoroscopic
ndings. In most patients, a rapid improvement in clini-
al status was observed; however, ﬁbrinolysis was usually
ontinued until TTE and cineﬂuoroscopic data normaliza-
ion. The main contraindications for ﬁbrinolysis were recent
urgery, recent delivery, severe hypertension, and haemor-
hage or recent massive stroke.
The following deﬁnitions were used:
‘‘full haemodynamic success’’: haemodynamic normal-
ization, conﬁrmed by cineﬂuoroscopy, TTE and/or TEE;
‘‘incomplete haemodynamic success’’: signiﬁcant clinical
improvement without complete recovery of disc or leaﬂet
motion at ﬂuoroscopy, TTE and/or TEE;
‘‘failure’’: absence of clinical improvement, eventually
associated with death or complications;
in some cases, ﬁbrinolysis produced haemodynamic nor-
malization but ‘‘failed’’ due to severe complications;
these patients were classiﬁed as ‘‘haemodynamic success
with complications’’.
Operative procedures have been described in details
lsewhere [35]. We deﬁned as ‘‘full haemodynamic success’’
neventful surgery and ‘‘failure’’ as death or complica-
ion.
tatistical analysis
arly clinical evolution was assessed during the period of
ospitalization. Data analysis was performed by a number of
pisodes (n = 263), assuming the hypothesis of independence
ith regard to patients’ clinical characteristics. Unless oth-
rwise speciﬁed, data are presented as means± S.D. or
ercentages. Comparisons between groups were performed
ith the use of Student’s t-test or the chi-square test, as
ppropriate. All p-values were two-sided and values less
han 0.05 were considered to indicate statistical signiﬁ-
ance.
A total of 210 patients were prospectively followed up.
ata analysis was performed by intention-to-treat. Three
atients who died immediately and 23 lost to follow-up
ere excluded for the long-term follow-up study. Long-term
ollow-up was evaluated by telephone or mail contact with
he consulting physician, with a mean survey duration of
years (median 5; ﬁrst interquartile 1; third interquar-
ile 10; maximum 20 years). For assessment of outcome,
he endpoints were recurrence and death. Deaths were
lassiﬁed as due to cardiac or extracardiac causes. The
umulative survival plot in relation to treatment (ﬁbri-
olysis or surgery) was estimated using the Kaplan-Meier
ethod, with use of the log-rank test. Hazard-risk ratios
ere estimated by Cox regression analysis. Multivariable
nalyses were done either by logistic regression or propor-
ional hazard regression, with backward stepwise variable
election and a p cut-off set to 0.10. Variables included
n the model were age, sex, ﬁbrinolysis versus surgery,
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Table 1 Main characteristics of patients with prosthetic heart valve thrombosis.
Population Surgery (n = 136 cases) Fibrinolysis (n = 127 cases) p
Prostheses (n)




Mitral 90 79 NS
Aortic 38 46
T 2 02
M-A 05 0 NS
M-T 1 0
Women/men (n) 86/50 82/45 NS
Mean age (years) 59± 15 57± 17 NS
Class III—IV (NYHA) (%) 62.5 70.8 NS
Delay (years)a 7.4± 6.7 4.3± 4.2 <0.001
































total cases, in 37 of 46 (80%) aortic valves, in 52 of 80
(65%) mitral valves, and in two of two (100%) tricuspid
prostheses. ‘‘Success’’ was obtained in 62 (48%) patients
with a single ﬁbrinolytic agent and in 28 patients using
a second or a third agent consecutively (combined ther-
apy). ‘‘Incomplete haemodynamic success’’ was obtained in
22 (17.3%) patients and ‘‘failure’’ of ﬁbrinolysis was noted
in 15 (11.8%) patients, both situations usually leading to
surgery. Major bleeding occurred in six (4.7%) patients: two
brain haemorrhages (1 death) and four peripheral haemor-
rhages (2 deaths). Systemic embolism was observed in 19
(15%) patients: six transient ischaemic attacks, eight strokes
leading to permanent disability (n = 1) or death (n = 7) and
ﬁve episodes of peripheral embolism. Death occurred in 15
(11.8%) patients due to primary failure of ﬁbrinolysis in ﬁve
and to complications in 10 (7 strokes, 3 haemorrhages). Sec-
ondary surgery was needed in 21 patients, due to failure or
incomplete success of ﬁbrinolysis.
Surgical group
‘‘Full haemodynamic success’’ was obtained in 122 of 136
(89%) patients. Surgical complications were 14 operative or
perioperative deaths (10.3%): four occurred in patients in
Table 2 Distribution of cases over time (1978 to 2001)
in our institution according to management by surgery or
ﬁbrinolysis.
Period Surgery Fibrinolysis Total
1978 to 1989 (pre-TEE) (n) 39 74 126a Mean time delay since implantation.
YHA functional class at presentation, atrial ﬁbrillation,
eft ventricular function, embolic episode, mitral valve
rosthesis and associated coronary artery bypass graft.
All authors participated in the study design, in the col-
ection and analysis of data, and in writing the manuscript.
esults
etween 1978 and 2001, we documented 263 episodes of
HVO in 210 patients; most cases were left-sided (Table 1).
ne hundred and twenty-seven episodes (in 110 patients)
ere treated with ﬁbrinolysis and 136 were treated with
urgery (primary surgery in 99 patients and secondary
urgery in 37 patients due to failure of ﬁbrinolysis (n = 21) or
eparin infusion (n = 16). Fibrinolysis was used in 127 cases
49 streptokinase, 41 urokinase and 37 rtPA as the ﬁrst agent)
nd a second or a third regimenwas used in 38 patients (com-
ination therapy). Operative procedures were performed
n 136 patients and comprised either valve replacement
n = 106) (with a mechanical or bioprosthetic valve) or
eclotting-pannus excision (n = 30).
During the 1980s, ﬁbrinolysis was usually used as the
rst-line treatment for PHVO in our institution because
f the high risk associated with surgery. However, since
990, with the introduction of TEE in the management of
hese patients, surgery became the preferred therapeu-
ic strategy. Hence, the management of patients during
hese two periods was signiﬁcantly different (Table 2). Early
esults were analysed according to the total number of cases
thrombotic episodes) treated by either ﬁbrinolysis (n = 127)
r surgery (n = 136) (Table 3).ibrinolytic group
‘Full haemodynamic success’’ with one or more consecu-
ive ﬁbrinolytic regimens was obtained in 90 of 127 (70.9%)
1990 to 2001 (post-TEE) (n) 97 53 137
Total (n) 136 127
Chi-square test: < 0.001.
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Table 3 Immediate results: comparison between the two groups.
Surgery (n = 136 cases) Fibrinolysis (n = 127 cases) p
Complete success (%) 122 (89) 90 (70.9) < 0.001
Incomplete success (%) 0 (0) 22 (17.3) < 0.001
Failure (%) 14 (10.3) 15 (11.8) NS
Total complicationsa (%) 16 (11.1) 32 (25.2)a 0.005
Haemorrhage (%) 1 (0.7) 6 (4.7) 0.08
Embolism (%) 1 (0.7) 19 (15.0) < 0.001













da Some patients had two complications.
functional class I to III and 10 in class IV (p < 0.001). Systemic
embolism was observed in one (0.7%) patient.
Overall, comparison of early results between ﬁbrinolysis
and surgery underline better initial results in the surgical
group, no signiﬁcant differences between the two groups
in terms of death and a signiﬁcantly higher rate of embolic
episodes and total complications in the ﬁbrinolysis group.
Early results in the pre-TEE and TEE eras
We compared both treatment modalities before and after
the introduction of TEE (Table 4). No signiﬁcant difference
was observed between both periods, except for a lower ‘‘full
haemodynamic success rate’’ with ﬁbrinolysis in the TEE
era. This may be explained by the fact that after initial
improvement due to the ﬁrst ﬁbrinolytic regimen surgery






Table 4 Immediate results, comparison between the two gro
Fibrinolysis













Complications n (%) Haemorrhage
Embolism
Death
TotalLong-term data were analysed by intention-to-treat,
onsidering the total number of patients surviving the
arly follow-up period (n = 107 for ﬁbrinolysis and n = 103
or surgery). The cumulative patient follow-up was
042 patient-years (range: 1—20). Twenty-three patients
ere lost (eight in the ﬁbrinolytic group; 15 in the
urgical group) to follow-up, accounting for 89% com-
lete long-term follow-up. ‘‘Recurrences’’ occurred in 24
24.7%) patients in the ﬁbrinolytic group, with a mean delay
f 2.6 years (range: 3months to 7 years). Among these
atients, 15 were treated with ﬁbrinolysis, ﬁve under-
ent surgery, two were treated with heparin, and two
ied early after hospital arrival. ‘‘Recurrences’’ occurred
n 10 (11.5%) patients in the surgical group, corresponding
o six of 32 patients after declotting and in four of 114
fter valve replacement (p < 0.003). Fibrinolysis was there-
ore associated with a signiﬁcantly higher rate of recurrence
p = 0.021).
ups, between pre-TEE and TEE eras.
Pre-TEE TEE p
91 (71.7) 58 (78) 33 (62) 0.047
22 (17.3) 9 (12) 13 (25) 0.07
14 (11.0) 7 (9) 7 (13) NS
127 (100) 74 (100) 53 (100) 0.12
6 (4.7) 3 (4.1) 3 (6) NS
19 (15.0) 12 (16.2) 7 (13) NS
15 (11.8) 8 (10.8) 7 (13) NS
32 (25.2) 19 (25.7) 13 (25) NS
121 (89.0) 36 (92) 85 (88) 0.43
0 (0.0) 0 (0) 0 (0) —
15 (11.0) 3 (8) 12 (12) 0.43
136 (100) 39 (100) 97 (100) —
1 (0.7) 1 (2.6) 0 (0) 0.11
1 (0.7) 0 (0.0) 1 (1) NS
14 (10.3) 3 (7.7) 11 (11) NS
15 (11.0) 3 (7.7) 12 (12) 0.43
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Table 5 Main complications during long-term follow-up (intention-to-treat).
Complications (n) Fibrinolysis (n = 97 patients)a Surgery (n = 87 patients)a p
Recurrence 24 10 0.021
Cardiac death 32 15 0.014
Non-cardiac death 15 8 0.20


















































































a Excluding 23 lost to follow-up and three who died immediately.
‘‘Late death’’ occurred in 70 patients, corresponding to
7 patients in the ﬁbrinolysis group and 23 in surgical group
p = 0.002; Table 5 and Fig. 1). During this period, 47 cardiac
eaths were reported (39 due to progressive left ventric-
lar failure and eight sudden deaths due to reobstruction)
hereas 23 patients died from an extracardiac pathology.
Long-term follow-up showed signiﬁcantly better results
n the surgical group. When considering late deaths, there
ere no signiﬁcant differences between the two groups in
erms of age, delay between PHVO and surgery, NYHA func-
ional class, history of previous coronary artery bypass graft
r echocardiographic data (data not shown).
In univariate analysis, factors associated with mortal-
ty were ﬁbrinolysis versus surgery and NYHA functional
lass at presentation (p < 0.01). No association was observed
or age, sex, atrial ﬁbrillation, left ventricular function,
mbolic episode, mitral valve prosthesis or associated coro-
ary artery bypass. In multivariable analysis, by logistic
egression or proportional hazard regression, the only factor
ssociated with mortality was NYHA functional class (hazard
atio: 1.60; 95% conﬁdence interval; p = 0.035).
iscussion
rosthetic heart valve thrombosis is a serious complica-
ion of valvular replacement and its optimal management
emains controversial. This extensive single-centre study is
he largest comparing surgical treatment with ﬁbrinolytic
herapy in patients with PHVO. By providing long-term
ollow-up in a large cohort of patients, it helps to better
eﬁne the most appropriate treatment modality.
The early results indicate that 70.9% of patients
ad complete resolution of haemodynamic abnormalities
ith ﬁbrinolysis. However, 11.8% died, 15% presented
ocumented embolic events and 4.7% suffered severe haem-
rrhagic complications. Overall, early complications were
bserved in 25.2% of patients. In an earlier study, we
ound no signiﬁcant difference in efﬁcacy of ﬁbrinolysis
or tilting discs or bileaﬂet valve prostheses [14]. Surgery
as successful in 89% of patients, with an early mortality
ate of 10.3%. Overall early complications (haemorrhage,
mbolism, death) occurred in only 11.1% (p < 0.005 versus
brinolysis).There were no signiﬁcant differences between ﬁbrinoly-
is and surgery when comparing time periods (pre-TEE and
ith TEE), except for a lower complete success rate with
brinolysis in the TEE era. Although surprising, this ﬁnd-




setecting residual thrombus. Furthermore, in cases of con-
raindication to surgery, the ﬁndings of TEE did not affect
he therapeutic strategy chosen.
As far as long-term follow-up is concerned, signiﬁcantly
etter outcomes in terms of recurrence and death were
bserved in the surgical group. Our results conﬁrm the risks
ssociated with ﬁbrinolysis of both early (thromboembolic
vents) and long-term complications (recurrences). In uni-
ariate and multivariable analyses, NYHA functional class
t presentation was a strong predictor of late mortality.
e believe that surgery should be the ﬁrst-line therapy for
HVO. However, ﬁbrinolysis may be an attractive alternative
n selected cases. Concerning ﬁbrinolysis, it is well known
hat fresh thrombus anywhere in the body has a higher
hance of being successfully treated by ﬁbrinolysis if the
hrombus is younger than 14 days approximately [35]. Fur-
hermore, according to Vitale et al. [11], in almost 50% of
he cases, thrombus is associated with a pannus and this
ssociation requires surgery.
Finally, this report has some ‘‘limitations’’: while it is
retrospective, non-randomized study, it is the largest
ingle-centre series reported in the literature comparing ﬁb-
inolysis and surgery in PHVO, with a follow-up of 20 years.
prospective randomized trial comparing ﬁbrinolysis and
urgery would be difﬁcult to carry out, as the number of
ases of PHVO in a single centre is limited and many factors
ffect the ﬁnal therapeutic decision (such as contraindica-
ions to either surgery or ﬁbrinolysis).
Our results are in agreement with those reported in the
iterature. Concerning the risk of ﬁbrinolysis, the review of
00 published reports of left-sided PHVO treated with ﬁbri-
olysis [16] showed an 82% initial success rate, an overall
hromboembolism rate of 12% and a mortality rate of 10%.
his consensus conference indicated that ﬁbrinolysis of left-
ided PHV is generally accepted for critically ill patients in
unctional class III or IV in whom surgical intervention carries
high risk or in patients with contraindications to surgery.
he argument against ﬁbrinolysis in patients in functional
lass I or II is based on the relatively low surgical mortality in
his group as opposed to a 12 to 17% embolic risk associated
ith ﬁbrinolysis with a risk of permanent disability.
According to Deviri et al. [9], who reported their expe-
ience with 100 patients undergoing surgical treatment for
bstruction of various types of currently used mechanical
alves, early mortality was 12.3% with a perioperative mor-
ality rate of 17.5% in patients with functional class IV and
.7% for functional classes I to III.
Few studies have directly compared ﬁbrinolysis and
urgery [36—41] and in these series, surgery was the
Management of prosthetic heart valve obstruction: Fibrinolysis v
Figure 1. Kaplan-Meier analysis of overall survival among patients
treated by surgery (. . .) or ﬁbrinolysis (. . .).
Top: total death, p = 0.038.






















































referred treatment in more than two-thirds of patients,
endering comparison difﬁcult. Renzulli et al. recently pub-
ished [38] their 23-year experience of 227mostly surgical
ases of PHVO in 206 patients. Surgery was indicated as
rst-line therapy in 201 (88.5%) cases and ﬁbrinolysis with
tPA was attempted in 26 cases. Their results show that
urgery still carries a signiﬁcant risk with an operative
ortality of 12.6%, but appears safer than ﬁbrinolysis.
ibrinolysis was successful in only 14 (53.8%) cases and ﬁve
ases of embolic complications were observed.
In a study of mostly symptomatic patients, the majority
f whom had obstructive PHVO, Lengyel and Vandor [40]
howed that mortality was 5% after ﬁbrinolysis (2 of 43 cases)
nd 30% after surgery (6 of 20 cases).
Finally, the Montreal Heart Institute recently published
heir 20-year experience in 39 cases of PHVO [41]. In this
tudy, 82% of patients underwent surgery and the 30-day
perative mortality was 25%. Fibrinolysis was attempted
s a deﬁnitive treatment in six patients generally because
f their poor overall medical condition. In the ﬁbrinoly-
is group, two (32%) patients died, three (50%) were sent
or surgery after failure of ﬁbrinolysis and another patient
as transferred to the operating room while receiving ﬁb-
inolysis. The authors concluded that surgery remains the
ainstay of treatment for patients with PHVO. Fibrinolysis
an be reserved for patients necessitating transfer to a ter-
iary care centre. In this study, the 10-year actuarial survival
ate was 46± 10%. The cause of long-term death was sudden
eath in three patients, whereas three others had a recur-
ence of valve thrombosis and died. Finally, TEE ﬁndings can
e important in guiding therapy and risk-stratifying patients,
s shown by Tong et al. [22]. In a study of 107 patients with
HVO, thrombus size imaged by TEE was a signiﬁcant inde-
endent predictor of outcome: a thrombus area less than
.8 cm2 identiﬁed patients at lower risk for complications
rom ﬁbrinolysis irrespective of NYHA functional class.
ight-sided PHVO [41]
ibrinolysis is usually the ﬁrst-line therapy in right-sided
alve obstruction except for ﬁrst generation prostheses or
tuck valve with pannus formation. Surgery with implanta-
ion of a bioprosthetic valve may be considered in cases of
ailed ﬁbrinolysis.
eft-sided PHVO
urgery is usually the favoured treatment for left-sided pros-
hetic valves, particularly in cases of chronic obstruction or
arly postoperative obstruction. Optimal management may
ake into account six parameters:
NYHA class;
thrombus within 14 days;
distance from surgical center;
type of prosthesis (generation, thrombogenicity);
thrombus size pannus on TEE;
contraindication to surgery (poor general condition).
Surgery is the ﬁrst-line therapy in cases of pannus or large










































in critically ill patients with acute obstruction if surgery
cannot be performed urgently (rescue ﬁbrinolysis);
if there are contraindications to surgery (such as low
cardiac output, respiratory insufﬁciency or multiple reop-
erations).
We also believe that ﬁbrinolysis may also be proposed for
linically stable patients after elimination of a large throm-
otic burden by TEE depending on the physician’s and/or
atient’s preference [15]. Furthermore, according to Reddy
t al. [17], ﬁbrinolysis could be a relevant alternative for
eveloping countries with limited economic resources.
onclusions
alve obstruction is one of the most serious complications of
mechanical prosthetic valve. Recent studies have under-
ined the heterogeneity of anatomical lesions (thrombus,
annus) and the wide spectrum of clinical presentations.
he advent of new and more accurate diagnostic proce-
ures, TEE in particular, has allowed better selection of
herapeutic options. According to the recommendations,
urgery is the favoured treatment for left-sided PHVO. How-
ver, ﬁbrinolysis may be justiﬁed in cases of tricuspid valve
bstruction and in selected cases of left-sided PHVO, namely
ritically ill patients in whom surgery cannot be performed
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